Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
The first six months of 2021 were another period of solid performance for UCB. We kept our pipeline on track. Read our latest financial results https://t.co/Et85ZQ2NSN https://t.co/TOmZwBfKCh
— UCB News (@ucb_news) 29.07.2021 -
Unsure on how to build a long-term game plan to manage a chronic inflammatory disease? Click below to access the #AdvantageHers questionnaire and helpful resources! https://t.co/dATkZnFwko
— UCB News (@ucb_news) 23.07.2021 -
Did you know that rheumatoid arthritis (RA) is three times more common in women than men? Find out more about the burden of RA and other chronic inflammatory diseases and how to build a game plan to manage them at https://t.co/33gbJ56QXW
— UCB News (@ucb_news) 16.07.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
